FeesSafety
Pluang+

AstraZeneca invests $2B in Summit Therapeutics to advance next-gen cancer drug ivonescimab.

Market News
05 Oct 2026, 22:44 WIB
CNBC
View Source
Bullish
AstraZeneca invests $2B in Summit Therapeutics to advance next-gen cancer drug ivonescimab.

AstraZeneca announced a $2 billion equity investment and clinical collaboration with Summit Therapeutics to develop ivonescimab, a first-in-class bispecific antibody for cancer treatment. This drug targets two cancer pathways simultaneously, potentially outperforming existing therapies like Merck's Keytruda. AstraZeneca plans to combine ivonescimab with its antibody-drug conjugates to enhance cancer treatment options. The investment grants AstraZeneca a 12% stake in Summit but allows Summit to retain full commercial rights. Additionally, AstraZeneca opened a $1 billion R&D facility in Cambridge, Massachusetts, focused on accelerating drug discovery with AI and robotics.

As of Oct 06, 2026 03:02 WIB, AstraZeneca (AZN) trades near its 52-week low at USD 157.01, down 0.44% for the day, while Summit Therapeutics (SMMT) is up 2.92% at USD 17.25, closer to its 52-week low of USD 12.43 than its high of USD 26.38. Despite AstraZeneca's large market cap of $242.94 billion compared to Summit's $13.49 billion, Summit sees a much shorter typical hold time on Pluang (17 days vs. 126 days) and full buy order activity, reflecting different investor engagement levels as of the same timestamp.

More News (AZN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App